

MABCURE ESTABLISHES BELGIAN SUBSIDIARY AND RELOCATES HEADQUARTERS TO BELGIUM

Reno, Nevada (October 30, 2008) MabCure Inc. (the "Company" or "MabCure") (OTCBB: MBCI.OB).

MabCure Inc. is pleased to announce the establishment of MabCure, N.V., a wholly-owned subsidiary in Belgium. The Company's President and Chief Executive Officer, Dr. Amnon Gonenne, has been appointed Director and Chief Executive Officer of the Belgian subsidiary. Dr. Elisha Orr, a cancer researcher and the developer of the Company's antibody technology, has been appointed Director and Chief Scientific Officer of the Belgian subsidiary.

The Belgian subsidiary was established in order to accelerate the development and commercialization of MabCure's proprietary products for the early detection of cancer with specific antibodies and for the creation of highly specific therapeutics (antibodies and novel drugs) against cancer. MabCure N.V. will be eligible to apply for research grants from the Flemish Government.

The Belgian subsidiary will be located on the Biomed campus of the University of Hasselt, which is well-known for its biomedical research activities. In addition to its own R&D program, MabCure N.V. plans to develop joint projects with the University of Hasselt, deploying MabCure's technology. MabCure's global headquarters will be relocated to Hasselt, Belgium as well.

About MabCure

MabCure is a biotechnology company whose vision is to change the perception of cancer as a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (Mabs) which will be developed as diagnostic tools, imaging agents and drugs to treat lethal cancers. MabCure initial goal is to develop its novel Mabs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company's website www.mabcure.com.

For further information, please contact: info@mabcure.com

This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, statements as to the intended uses of the proceeds received from the private placement.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company and the inability of the Company to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.